☆ 4.7 Article

Adverse Reactions after BNT162b2 Messenger RNA Vaccination for Coronavirus Disease 2019 in Healthcare Workers Compared with Influenza Vaccination

VACCINES (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

Edson D. Moreira et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

L. J. Abu-Raddad et al.

Summary: A study in Qatar showed that booster vaccination significantly reduced the incidence of infection with the omicron variant, providing strong protection against Covid-19-related hospitalization and death. Booster effectiveness was observed for both mRNA vaccines, BNT162b2 and mRNA-1273, with lower infection rates and reduced severity of cases among those who received the booster dose.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Clinical Neurology

Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis

Lingyao Kong et al.

Summary: This study indicates that inactivated SARS-CoV-2 vaccines appear to be safe for patients with CNS demyelinating diseases.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Add to Collection

Article Immunology

A Case Presenting with Neuromyelitis Optica Spectrum Disorder and Infectious Polyradiculitis Following BNT162b2 Vaccination and COVID-19

Youngho Kim et al.

Summary: A 37-year-old woman experienced paraparesis and paresthesia in both legs after receiving the BNT162b2 vaccine and being infected with SARS-CoV-2. Through various tests and treatment, including intravenous methylprednisolone and antiviral agents, the patient regained the ability to walk.

VACCINES (2022)

Add to Collection

Article Immunology

Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system

Congqin Chen et al.

Summary: This study compares the incidence rates and risks of myocarditis/pericarditis between booster and primary vaccination programs for COVID-19 mRNA vaccines. The results show that the booster dose does not increase the risks of myocarditis/pericarditis compared to the primary series.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Clinical Features of Patients Presenting to the Emergency Department With Cardiovascular Adverse Reactions After COVID-19 mRNA Vaccination

Tae Hoon Oh et al.

Summary: Since the implementation of the COVID-19 mRNA vaccination, emergency departments have seen an increasing number of patients reporting cardiovascular adverse effects. Most of these patients were discharged from the emergency department, but some required hospital admission. The admission rate was higher in males than in females.

JOURNAL OF KOREAN MEDICAL SCIENCE (2022)

Add to Collection

Article Clinical Neurology

Longitudinal extensive transverse myelitis following ChAdOx1 nCOV-19 vaccine: a case report

Wee Yong Tan et al.

Summary: Transverse myelitis (TM) is a rare condition, and vaccine-associated myelitis is even rarer. Concerns about neurological complications following vaccination increased after the report of TM during COVID-19 vaccine trials. The first case of Longitudinal Extensive Transverse Myelitis (LETM) in Malaysia occurred following vaccination with the ChAdOx1 nCoV-19 vaccine, but the patient eventually recovered with treatment. While LETM following vaccination is rare, cases have shown symptoms onset between 10 to 14 days post-vaccination, suggesting a delayed immunogenic reaction.

BMC NEUROLOGY (2021)

Add to Collection

Editorial Material Clinical Neurology

ANA Investigates: Neurological Complications of COVID-19 Vaccines

Adeline L. Goss et al.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Waning Immunity after the BNT162b2 Vaccine in Israel

Yair Goldberg et al.

Summary: The immunity against the delta variant of SARS-CoV-2 waned in all age groups in Israel a few months after receiving the second dose of the vaccine, leading to an increase in infection and severe cases.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Barak Mizrahi et al.

Summary: The study indicates preliminary evidence of waning vaccine effectiveness of BNT162b2 among all age groups above 16, with a higher incidence of infection in those vaccinated earlier in 2021. Further investigation into long-term protection against different strains is warranted.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Infectious Diseases

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Cristina Menni et al.

Summary: This study investigated the safety and effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines in a UK community setting. The results showed that the frequencies of side effects from these vaccines were lower than reported in clinical trials, and a significant reduction in the risk of SARS-CoV-2 infection was observed starting at 12 days after vaccination.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Medicine, General & Internal

COVID-19 vaccination-associated myelitis

Hardeep Singh Malhotra et al.

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2021)

Add to Collection

Article

Post COVID-19 vaccination neuromyelitis optica spectrum disorder: Case report & MRI findings

Noor Badrawi et al.

Radiology Case Reports (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

S. J. Thomas et al.

Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV

Mohammad Ali Sahraian et al.

Summary: This study investigated adverse events after the first dose of Sinopharm COVID-19 vaccine among 583 Iranian MS patients, finding that most vaccine recipients reported at least one complaint, with constitutional symptoms and headache being the most common complaints. There was a correlation between gender, prior COVID-19 infection, and reported symptoms. Only a small number of recipients reported MS relapse post-vaccination, with MS worsening being linked to fever as a minor incident.

VACCINE (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19 booster vaccines: What we know and who's doing what

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021

Julia W. Gargano et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Medicine, General & Internal

Systemic Adverse Events and Use of Antipyretics Predict the Neutralizing Antibody Positivity Early after the First Dose of ChAdOx1 Coronavirus Disease Vaccine

Ji Young Park et al.

Summary: In a medical center in Korea, the majority of healthcare workers who received the ChAdOx1 COVID-19 vaccine reported experiencing adverse events, while 81.3% tested positive for neutralizing antibodies 33-40 days post-vaccination. Those who tested positive for neutralizing antibodies reported systemic adverse events and more frequently used acetaminophen.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Immunology

Acute Transverse Myelitis Following COVID-19 Vaccination

Jhih-Jian Gao et al.

Summary: Concerns have been raised over adverse reactions following COVID-19 vaccination, including transverse myelitis. Current research suggests that these reactions may be related to autoimmune responses.

VACCINES (2021)

Add to Collection

Article Medicine, General & Internal

Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older

Youn Young Choi et al.

Summary: The study examined the safety of the COVID-19 vaccine for adults aged 75 and older who received two doses at a vaccination center in South Korea. The frequency of acute adverse reactions within 15-30 minutes after injection was 8.5 cases per 1,000 doses, with most reactions not requiring special treatment.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea

Yun Woo Lee et al.

Summary: This study found that the rate of adverse reactions in healthcare workers after receiving both doses of the BNT162b2 mRNA vaccine significantly increased after the second dose, especially muscle ache, fatigue, headache, chills, and fever. Females had a significantly higher frequency of adverse reactions after the second dose, while older age groups had lower rates of adverse reactions.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea

Seongman Bae et al.

Summary: A prospective survey conducted in South Korea on healthcare workers who received the first dose of two COVID-19 vaccines showed a higher rate of adverse reactions in the ChAdOx1 group compared to the BNT162b2 group. Females and younger age groups were more likely to experience vaccine-associated adverse reactions.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

Add to Collection

Letter Immunology

Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases

Aristo Vojdani et al.

CLINICAL IMMUNOLOGY (2020)

Add to Collection

Review Behavioral Sciences

Neurotropism of SARS-CoV-2 and its neuropathological alterations: Similarities with other coronaviruses

Jingman Hu et al.

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2020)

Add to Collection

Review Immunology

The how's and what's of vaccine reactogenicity

Caroline Herve et al.

NPJ VACCINES (2019)

Add to Collection

Article Immunology

Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis

Roger Baxter et al.

CLINICAL INFECTIOUS DISEASES (2016)

Add to Collection

Review Infectious Diseases

The Xs and Y of immune responses to viral vaccines

Sabra L. Klein et al.

LANCET INFECTIOUS DISEASES (2010)

Add to Collection

Article Rheumatology

Transverse myelitis and vaccines: a multi-analysis

N. Agmon-Levin et al.

LUPUS (2009)

Add to Collection

Article Immunology

Fever after immunization: Current concepts and improved future scientific understanding

KS Kohl et al.

CLINICAL INFECTIOUS DISEASES (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.